A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effects (good and bad) of the combination of
docetaxel and carboplatin for patients who have progressive prostate cancer after
chemotherapy with drugs such as docetaxel. The investigators are also studying whether the
measurement of two proteins in the blood may predict who will respond to the combination of
docetaxel and carboplatin.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Bristol-Myers Squibb Lowell General Hospital Massachusetts General Hospital Oregon Health and Science University Wentworth-Douglass Hospital